These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28083936)

  • 1. ADHD medications and cardiovascular adverse events in children and adolescents: cross-national comparison of risk communication in drug labeling.
    Sieluk J; Palasik B; dosReis S; Doshi P
    Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):274-284. PubMed ID: 28083936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
    Martinez-Raga J; Knecht C; Szerman N; Martinez MI
    CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
    Hammerness PG; Perrin JM; Shelley-Abrahamson R; Wilens TE
    J Am Acad Child Adolesc Psychiatry; 2011 Oct; 50(10):978-90. PubMed ID: 21961773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study.
    Dalsgaard S; Kvist AP; Leckman JF; Nielsen HS; Simonsen M
    J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):302-10. PubMed ID: 24956171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADHD drugs and cardiovascular risk.
    Rappley MD; Moore JW; Dokken D
    N Engl J Med; 2006 May; 354(21):2296-8; author reply 2296-8. PubMed ID: 16729375
    [No Abstract]   [Full Text] [Related]  

  • 6. Attention deficit hyperactivity disorder medications in children with heart disease.
    Berger S
    Curr Opin Pediatr; 2016 Oct; 28(5):607-12. PubMed ID: 27261563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulant use following the publicity of cardiovascular safety and the introduction of patient medication guides.
    Chen CY; Bussing R; Hartzema AG; Shuster JJ; Segal R; Winterstein AG
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):678-86. PubMed ID: 26597624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADHD drugs and cardiovascular risk.
    Anders T; Sharfstein S
    N Engl J Med; 2006 May; 354(21):2296-8; author reply 2296-8. PubMed ID: 16723628
    [No Abstract]   [Full Text] [Related]  

  • 9. Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?
    Hammerness PG; Karampahtsis C; Babalola R; Alexander ME
    Expert Opin Drug Saf; 2015 Apr; 14(4):543-51. PubMed ID: 25648243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medications for attention deficit hyperactivity disorder: cardiovascular concerns.
    Wooltorton E
    CMAJ; 2006 Jul; 175(1):29. PubMed ID: 16772535
    [No Abstract]   [Full Text] [Related]  

  • 11. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN; Wilde AA
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1713-4. PubMed ID: 16924941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiovascular risk assessment for the use of ADHD drugs in children].
    Berg A; Bråtane E; Odland HH; Brudvik C; Rosland B; Hirth A
    Tidsskr Nor Laegeforen; 2014 Apr; 134(7):710-4. PubMed ID: 24721858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis.
    Zhang L; Yao H; Li L; Du Rietz E; Andell P; Garcia-Argibay M; D'Onofrio BM; Cortese S; Larsson H; Chang Z
    JAMA Netw Open; 2022 Nov; 5(11):e2243597. PubMed ID: 36416824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications.
    McAfee AT; Landon J; Jones M; Bangs ME; Acharya N; Hornbuckle K; Wong J
    Pharmacoepidemiol Drug Saf; 2013 Apr; 22(4):386-93. PubMed ID: 23280590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulant therapy in children with attention-deficit/hyperactivity disorder and concomitant long QT syndrome: A safe combination?
    Rohatgi RK; Bos JM; Ackerman MJ
    Heart Rhythm; 2015 Aug; 12(8):1807-12. PubMed ID: 25956966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADHD drugs and serious cardiovascular events in children and young adults.
    Cooper WO; Habel LA; Sox CM; Chan KA; Arbogast PG; Cheetham TC; Murray KT; Quinn VP; Stein CM; Callahan ST; Fireman BH; Fish FA; Kirshner HS; O'Duffy A; Connell FA; Ray WA
    N Engl J Med; 2011 Nov; 365(20):1896-904. PubMed ID: 22043968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.
    Silva RR; Skimming JW; Muniz R
    Clin Pediatr (Phila); 2010 Sep; 49(9):840-51. PubMed ID: 20693523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009.
    Betts KA; Sikirica V; Hodgkins P; Zhou Z; Xie J; DeLeon A; Erder MH; Wu EQ
    J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):260-8. PubMed ID: 24839998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
    Hennessy S; Schelleman H; Daniel GW; Bilker WB; Kimmel SE; Guevara J; Cziraky MJ; Strom BL
    Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):934-41. PubMed ID: 20623519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.